SCHEMBL2870927

SCHEMBL2870927

N#Cc1c(Cl)c2ccc(O)cc2[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.47
KDM5C P41229 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
GRIN2D O15399 2/20 0.41
GRIN3B O60391 2/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN2C Q14957 2/20 0.41
GRIN3A Q8TCU5 2/20 0.41
HSD17B3 P37058 1/20 0.40
FASN P49327 1/20 0.40
GLI1 P08151 1/20 0.40
GLI2 P10070 1/20 0.40
PIM1 P11309 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359185 0.82 PDE9A (0.48) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL1621734 0.78 PDE9A (0.62) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL18584332 0.75 PTGES (0.49) KDM5BKDM4EALDH1A1GLAGAA
SCHEMBL359483 0.74 HSD11B1 (0.41) KDM4EALDH1A1GAAHPGDFASN
SCHEMBL359150 0.73 KDM5A (0.57) KDM5AKDM5CKDM5BKDM4EALDH1A1
SCHEMBL13025202 0.73 ALDH1A1 (0.44) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL2126317 0.73 KDM5A (0.57) KDM5AKDM5CKDM5BKDM4EALDH1A1
SCHEMBL4754631 0.73 KDM5A (0.69) KDM5AKDM5CKDM5BPDE9APARP1
SCHEMBL22206950 0.73 PIM1 (0.44) KDM4EALDH1A1HPGDPIM1PDE9A
SCHEMBL5529450 0.73 PDE9A (0.51) KDM4EALDH1A1HPGDPDE9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM5A 1193/4885KDM5C 1250/4885KDM5B 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.